Clevira, principally developed to treat dengue, has been repurposed to serve as a supportive treatment for mild to moderate COVID-19 patients, reported the drug’s manufacturer Apex Laboratories Private Limited. 

The drug is effective when taken orally and is given in a dosage of one tablet twice a day after food for 14 days. The drug has been found to be safe on liver and kidney parameters as well, said the company. The company reported that Clevira has been given regulatory approval as a supportive treatment for mild to moderate COVID-19 cases, adding that it is available across the country at a price ofRs 11 per tablet.

A clinical trial conducted with 100 people in May-June, 2020 noted that Cleviraled to a significant reduction in the time taken for clinical recovery, characterized by reduction in pyrexia or body pain, normalization of respiratory rate (<24/minute) and improvement in oxygen saturation level (>94%)… (ET Healthworld – PTI, April 30, 2021)